Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 721 results for innovative

  1. Path Finder for freezing of gait in people with Parkinson's disease (MIB170)

    NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .

  2. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

  3. 5 tips to help get your healthtech product to market, fast

    Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.

  4. Episcissors-60 for mediolateral episiotomy (HTG538)

    Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy.

  5. Prontosan for treating acute and chronic wounds (HTG616)

    Evidence-based recommendations on Prontosan for treating acute and chronic wounds.

  6. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  7. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.

  8. Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (TA1046)

    Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.

  9. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

  10. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

  11. Video laryngoscopes to help intubation in people with difficult airways (MIB167)

    NICE has developed a medtech innovation briefing (MIB) on video laryngoscopy to help intubation in people with difficult airways .

  12. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England

  13. OrganOx metra for liver transplant (MIB275)

    NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .

  14. Axumin for functional imaging of prostate cancer recurrence (MIB172)

    NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .

  15. ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)

    NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .